Bioinformatics Market Size, Share, Growth, and Industry Analysis, By Type (Knowledge Management Tools,Bioinformatics Platform,Bioinformatics Services), By Application (Metabolomics,Molecular Phylogenetics,Transcriptomics,Proteomics,Chemoinformatics,Genomics,Others), Regional Insights and Forecast to 2035

Bioinformatics Market Overview

The global Bioinformatics Market size is projected to grow from USD 12922 million in 2026 to USD 14636.75 million in 2027, reaching USD 39661.02 million by 2035, expanding at a CAGR of 13.27% during the forecast period.

The global bioinformatics market is experiencing significant growth, driven by advancements in genomics, proteomics, and personalized medicine. In 2025, the market is projected to reach USD 18.69 billion, reflecting a substantial increase from previous years. This growth is attributed to the rising demand for data analysis tools and services in the life sciences sector. Key factors include the integration of artificial intelligence (AI) in bioinformatics platforms and the increasing application of bioinformatics in drug discovery and development.

The United States holds a dominant position in the global bioinformatics market, accounting for a significant share due to its advanced healthcare infrastructure and substantial investments in research and development. In 2025, the U.S. bioinformatics market is estimated to be valued at USD 7.33 billion. The country's focus on precision medicine and the adoption of next-generation sequencing technologies contribute to this growth. Additionally, government initiatives and funding support further bolster the market's expansion in the region.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: The integration of AI and machine learning in bioinformatics is enhancing data analysis capabilities, leading to more efficient research outcomes.
• Major Market Restraint: High costs associated with bioinformatics tools and services pose challenges for widespread adoption, particularly in developing regions
• Emerging Trends: The shift towards cloud-based bioinformatics solutions is facilitating easier data sharing and collaboration among researchers globally.
• Regional Leadership: North America leads the market with a substantial share, followed by Europe and the Asia-Pacific region, reflecting the global distribution of bioinformatics advancements.
• Competitive Landscape: Major players such as Thermo Fisher Scientific, Illumina, and QIAGEN dominate the market, offering a wide range of bioinformatics solutions.
• Market Segmentation: The market is segmented into knowledge management tools, bioinformatics platforms, and bioinformatics services, each catering to specific needs within the life sciences sector.
• Recent Development: Advancements in single-cell genomics and the application of quantum computing in bioinformatics are opening new avenues for research and development.

Bioinformatics Market Latest Trends

The bioinformatics market is witnessing several notable trends in 2025. The adoption of AI and machine learning algorithms is revolutionizing data analysis, enabling researchers to process complex biological data more efficiently. Cloud computing is becoming increasingly prevalent, allowing for scalable and collaborative research efforts. Additionally, the integration of bioinformatics in personalized medicine is facilitating the development of targeted therapies, improving patient outcomes. The market is also seeing a rise in the use of bioinformatics tools in agricultural research, contributing to advancements in crop improvement and sustainability.

Bioinformatics Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The pharmaceutical industry's growing reliance on bioinformatics for drug discovery and development is a significant driver of market growth. Bioinformatics tools enable the analysis of vast datasets, aiding in the identification of potential drug targets and biomarkers. This accelerates the drug development process and enhances the precision of therapeutic interventions.

RESTRAINT

"Demand for refurbished equipment"

The preference for refurbished bioinformatics equipment in cost-sensitive markets can hinder the adoption of advanced technologies. This may limit the capabilities of research institutions and laboratories, affecting the overall progress in bioinformatics research and applications.

OPPORTUNITY

"Growth in personalized medicines"

The increasing emphasis on personalized medicine presents significant opportunities for the bioinformatics market. By leveraging genomic and proteomic data, bioinformatics facilitates the development of individualized treatment plans, enhancing the effectiveness of therapies and reducing adverse effects.

CHALLENGE

"Rising costs and expenditures"

The high costs associated with bioinformatics tools, data storage, and skilled personnel pose challenges for market expansion. Organizations must invest significantly to establish and maintain bioinformatics infrastructure, which can be a barrier, especially for smaller entities.

Bioinformatics Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Metabolomics: This segment focuses on the comprehensive analysis of metabolites in biological systems. Advancements in analytical techniques are enhancing the accuracy and throughput of metabolomic studies, contributing to its growing application in disease diagnosis and drug development.

The metabolomics segment is anticipated to reach USD 5,200 million by 2034, growing at a CAGR of 12.5% from 2025. It accounts for approximately 11% of the total market share, driven by increasing applications in disease biomarker discovery.

Top 5 Major Dominant Countries in the Metabolomics Segment

• United States: Expected to achieve USD 1,500 million by 2034, with a CAGR of 12.2%, holding a 28.8% share in the metabolomics market.
• Germany: Projected to reach USD 800 million by 2034, growing at a CAGR of 11.8%, contributing 15.4% to the segment.
• China: Forecasted at USD 700 million by 2034, expanding at a CAGR of 13.5%, representing 13.5% of the market.
• United Kingdom: Anticipated to attain USD 600 million by 2034, with a CAGR of 11.0%, accounting for 11.5% share.
• Japan: Expected to reach USD 500 million by 2034, growing at a CAGR of 10.9%, holding a 9.6% market share.

Molecular Phylogenetics: This area involves the study of evolutionary relationships among organisms using molecular data. Bioinformatics tools are essential in constructing phylogenetic trees and understanding genetic variations, aiding in biodiversity studies and evolutionary biology.

Molecular phylogenetics is projected to grow to USD 4,800 million by 2034, at a CAGR of 12.0% from 2025, comprising about 10% of the bioinformatics market, fueled by evolutionary studies and biodiversity research.

Top 5 Major Dominant Countries in the Molecular Phylogenetics Segment

• United States: Estimated at USD 1,400 million by 2034, with a CAGR of 11.8%, capturing 29.2% of the segment.
• Germany: Projected to reach USD 750 million by 2034, growing at a CAGR of 11.5%, contributing 15.6% to the market.
• China: Forecasted at USD 650 million by 2034, expanding at a CAGR of 12.8%, representing 13.5% share.
• United Kingdom: Anticipated to attain USD 550 million by 2034, with a CAGR of 10.7%, accounting for 11.5% of the segment.
• Japan: Expected to reach USD 450 million by 2034, growing at a CAGR of 10.5%, holding a 9.4% market share.

Transcriptomics: Transcriptomics examines the complete set of RNA transcripts produced by the genome. High-throughput sequencing technologies and bioinformatics analyses are enabling researchers to study gene expression patterns, contributing to insights into gene function and regulation.

The transcriptomics segment is expected to reach USD 6,000 million by 2034, growing at a CAGR of 13.0% from 2025, representing approximately 12.6% of the total market, driven by gene expression analysis advancements.

Top 5 Major Dominant Countries in the Transcriptomics Segment

• United States: Projected at USD 1,800 million by 2034, with a CAGR of 12.7%, capturing 30% of the segment.
• Germany: Estimated to reach USD 900 million by 2034, growing at a CAGR of 12.3%, contributing 15% to the market.
• China: Forecasted at USD 800 million by 2034, expanding at a CAGR of 13.8%, representing 13.3% share.
• United Kingdom: Anticipated to attain USD 700 million by 2034, with a CAGR of 11.9%, accounting for 11.6% of the segment.
• Japan: Expected to reach USD 600 million by 2034, growing at a CAGR of 11.7%, holding a 10% market share.

Proteomics: Proteomics involves the large-scale study of proteins, their structures, and functions. Bioinformatics tools assist in protein identification, quantification, and functional analysis, playing a crucial role in understanding cellular processes and disease mechanisms.

Proteomics is projected to grow to USD 7,500 million by 2034, at a CAGR of 13.5% from 2025, comprising about 15.8% of the bioinformatics market, driven by protein analysis in disease research.

Top 5 Major Dominant Countries in the Proteomics Segment

• United States: Estimated at USD 2,200 million by 2034, with a CAGR of 13.2%, capturing 29.3% of the segment.
• Germany: Projected to reach USD 1,100 million by 2034, growing at a CAGR of 12.8%, contributing 14.7% to the market.
• China: Forecasted at USD 1,000 million by 2034, expanding at a CAGR of 14.5%, representing 13.3% share.
• United Kingdom: Anticipated to attain USD 900 million by 2034, with a CAGR of 12.3%, accounting for 12% of the segment.
• Japan: Expected to reach USD 800 million by 2034, growing at a CAGR of 12.1%, holding a 10.7% market share.

Chemoinformatics: This field combines chemistry and computational techniques to analyze chemical data. Bioinformatics applications in chemoinformatics support drug discovery by predicting molecular properties and interactions, streamlining the development of new compounds.

The chemoinformatics segment is anticipated to reach USD 3,500 million by 2034, growing at a CAGR of 11.5% from 2025, accounting for approximately 7.4% of the total market, driven by drug discovery applications.

Top 5 Major Dominant Countries in the Chemoinformatics Segment

• United States: Projected at USD 1,000 million by 2034, with a CAGR of 11.2%, capturing 28.6% of the segment.
• Germany: Estimated to reach USD 600 million by 2034, growing at a CAGR of 10.8%, contributing 17.1% to the market.
• China: Forecasted at USD 500 million by 2034, expanding at a CAGR of 12.0%, representing 14.3% share.
• United Kingdom: Anticipated to attain USD 450 million by 2034, with a CAGR of 10.5%, accounting for 12.9% of the segment.
• Japan: Expected to reach USD 400 million by 2034, growing at a CAGR of 10.3%, holding an 11.4% market share.

Genomics: Genomics is the study of genomes, encompassing the sequencing, analysis, and interpretation of genetic material. Bioinformatics is integral in managing and analyzing genomic data, facilitating research in areas such as gene therapy and genetic engineering.

Genomics is expected to reach USD 15,000 million by 2034, growing at a CAGR of 14.0% from 2025, representing approximately 31.6% of the total market, driven by advancements in sequencing technologies.

Top 5 Major Dominant Countries in the Genomics Segment

• United States: Estimated at USD 4,500 million by 2034, with a CAGR of 13.7%, capturing 30% of the segment.
• Germany: Projected to reach USD 2,000 million by 2034, growing at a CAGR of 13.3%, contributing 13.3% to the market.
• China: Forecasted at USD 1,800 million by 2034, expanding at a CAGR of 14.8%, representing 12% share.
• United Kingdom: Anticipated to attain USD 1,500 million by 2034, with a CAGR of 12.9%, accounting for 10% of the segment.
• Japan: Expected to reach USD 1,200 million by 2034, growing at a CAGR of 12.7%, holding an 8% market share.

Others: This category includes emerging areas such as epigenomics and systems biology, where bioinformatics plays a pivotal role in integrating and interpreting complex biological data to understand regulatory mechanisms and network interactions.

The 'Others' category, encompassing emerging bioinformatics fields, is projected to reach USD 5,000 million by 2034, growing at a CAGR of 12.0% from 2025, accounting for approximately 10.5% of the total market.

Top 5 Major Dominant Countries in the Others Segment

• United States: Projected at USD 1,500 million by 2034, with a CAGR of 11.8%, capturing 30% of the segment.
• Germany: Estimated to reach USD 800 million by 2034, growing at a CAGR of 11.4%, contributing 16% to the market.
• China: Forecasted at USD 700 million by 2034, expanding at a CAGR of 12.5%, representing 14% share.
• United Kingdom: Anticipated to attain USD 600 million by 2034, with a CAGR of 11.0%, accounting for 12% of the segment.
• Japan: Expected to reach USD 500 million by 2034, growing at a CAGR of 10.8%, holding

BY APPLICATION

Knowledge Management Tools: These tools are designed to manage and organize vast amounts of biological data. They enable efficient data retrieval, sharing, and collaboration among researchers, enhancing the productivity and effectiveness of bioinformatics research.

The knowledge management tools segment is expected to reach USD 10,500 million by 2034, accounting for nearly 22.1% of the market and expanding at a CAGR of 12.8%, driven by increasing demand for organized biological data storage.

Top 5 Major Dominant Countries in the Knowledge Management Tools Application

• United States: Expected to reach USD 3,000 million by 2034, with a CAGR of 12.5%, accounting for 28.5% of the total segment due to advanced research infrastructures and large biotech companies.
• Germany: Projected at USD 1,400 million by 2034, growing at a CAGR of 12.0%, contributing approximately 13.3% to the global share in this application.
• China: Anticipated to hit USD 1,300 million by 2034, expanding at a CAGR of 13.4%, making up 12.3% of the segment driven by digitization initiatives in healthcare.
• United Kingdom: Forecasted at USD 1,000 million by 2034, at a CAGR of 11.3%, holding 9.5% of the market share due to a rising number of genomics-based research projects.
• Japan: Estimated to achieve USD 900 million by 2034, growing at a CAGR of 11.0%, contributing around 8.6% to the segment due to tech-driven research funding.

Bioinformatics Platform: Bioinformatics platforms provide integrated environments for data analysis, visualization, and interpretation. They support various applications, including sequence alignment, structural modeling, and functional annotation, facilitating comprehensive biological analyses.

The bioinformatics platform segment is anticipated to grow to USD 18,000 million by 2034, representing the largest share at 37.9%, with a CAGR of 14.2%, fueled by increasing use of AI and ML in drug discovery platforms.

Top 5 Major Dominant Countries in the Bioinformatics Platform Application

• United States: Expected to reach USD 5,500 million by 2034, with a CAGR of 14.0%, capturing 30.5% of the segment with robust platform innovation and integration.
• Germany: Projected at USD 2,300 million by 2034, growing at a CAGR of 13.6%, holding 12.7% share due to a strong pharma-tech ecosystem.
• China: Forecasted to reach USD 2,100 million by 2034, expanding at a CAGR of 15.0%, comprising 11.7% of the segment with growing platform-based start-ups.
• United Kingdom: Estimated at USD 1,700 million by 2034, at a CAGR of 13.1%, making up 9.4% share due to enhanced R&D collaborations.
• Japan: Anticipated to attain USD 1,500 million by 2034, growing at a CAGR of 12.9%, contributing around 8.3% to the segment via bioinformatics software development.

Bioinformatics Services: These services encompass a range of offerings, from data analysis and interpretation to consulting and training. They cater to organizations lacking in-house bioinformatics capabilities, providing access to expertise and resources necessary for advanced research.

The bioinformatics services segment is expected to reach USD 18,980 million by 2034, comprising nearly 40% of the total market, with a CAGR of 13.1%, due to the rising outsourcing of genomic and proteomic data analysis.

Top 5 Major Dominant Countries in the Bioinformatics Services Application

• United States: Estimated to grow to USD 5,700 million by 2034, with a CAGR of 13.0%, accounting for 30% share thanks to advanced service models and consultancy firms.
• Germany: Forecasted at USD 2,400 million by 2034, expanding at a CAGR of 12.7%, holding 12.6% share due to clinical informatics and contract research services.
• China: Expected to reach USD 2,300 million by 2034, with a CAGR of 14.3%, comprising 12.1% of the segment due to a booming biomedical service sector.
• United Kingdom: Anticipated at USD 1,800 million by 2034, with a CAGR of 12.1%, making up 9.5% of the total, driven by strategic alliances and government-funded genome projects.
• Japan: Projected to hit USD 1,600 million by 2034, growing at a CAGR of 11.9%, contributing 8.4% share due to bioinformatics applications in disease mapping and diagnostics.

Bioinformatics Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds the largest share in the bioinformatics market, attributed to its advanced research infrastructure and significant investments in biotechnology. The region's focus on personalized medicine and the presence of leading bioinformatics companies contribute to its market dominance. Additionally, supportive government policies and funding initiatives further bolster the growth of bioinformatics in North America.

North America is projected to dominate the global bioinformatics market, reaching USD 18,000 million by 2034, representing a 37.9% share, with a CAGR of 12.9%, led by innovations in genomics, proteomics, and AI-based platforms.

North America - Major Dominant Countries in the “Bioinformatics Market”

• United States: Expected to reach USD 14,000 million by 2034, with a CAGR of 13.0%, commanding over 77.7% of North America’s market due to research infrastructure and biotech presence.
• Canada: Estimated at USD 2,000 million by 2034, growing at a CAGR of 12.3%, holding 11.1% share in North America due to government-driven genomics research.
• Mexico: Forecasted to hit USD 1,100 million by 2034, with a CAGR of 11.8%, contributing 6.1% through pharmaceutical industry integration.
• Cuba: Projected at USD 500 million by 2034, expanding at a CAGR of 11.1%, driven by research collaborations and personalized medicine efforts.
• Costa Rica: Expected to achieve USD 400 million by 2034, with a CAGR of 10.8%, representing 2.2% of the North American market via biotech parks and academic centers.

EUROPE

Europe represents a significant portion of the bioinformatics market, driven by collaborative research initiatives and strong academic institutions. The region's emphasis on data privacy and ethical considerations in research fosters a conducive environment for bioinformatics advancements. Moreover, the European Union's funding programs support the development and integration of bioinformatics across various sectors.

Europe’s bioinformatics market is anticipated to grow to USD 13,000 million by 2034, with a CAGR of 13.0%, representing 27.4% of the global share, supported by strong academic research and biotechnology hubs.

Europe - Major Dominant Countries in the “Bioinformatics Market”

• Germany: Forecasted to reach USD 4,500 million by 2034, with a CAGR of 13.2%, representing 34.6% of Europe’s bioinformatics market due to heavy investments in biotech innovation.
• United Kingdom: Expected at USD 3,200 million by 2034, growing at a CAGR of 12.8%, accounting for 24.6% of regional share, supported by genomic data projects and AI integration.
• France: Estimated to hit USD 2,000 million by 2034, with a CAGR of 12.4%, comprising 15.3% share in Europe due to clinical informatics integration.
• Italy: Projected at USD 1,800 million by 2034, growing at a CAGR of 12.0%, holding 13.8% share through precision medicine initiatives.
• Spain: Anticipated to reach USD 1,500 million by 2034, at a CAGR of 11.6%, contributing 11.5% due to collaborative bioinformatics research centers.

ASIA-PACIFIC

The Asia-Pacific region is experiencing rapid growth in the bioinformatics market, fueled by increasing investments in healthcare infrastructure and research. Countries like China and India are emerging as key players, with expanding biotechnology sectors and government support for genomics research. The region's large population base and rising prevalence of chronic diseases further drive the demand for bioinformatics solutions.

Asia is expected to exhibit rapid growth, with its bioinformatics market set to reach USD 11,200 million by 2034, growing at a CAGR of 14.2%, accounting for 23.6% of the global market due to increased genomic projects.

Asia - Major Dominant Countries in the “Bioinformatics Market”

• China: Forecasted to reach USD 5,000 million by 2034, with a CAGR of 14.8%, representing 44.6% of the Asian market through digital health programs and sequencing initiatives.
• Japan: Estimated at USD 3,200 million by 2034, growing at a CAGR of 12.8%, holding 28.5% share supported by government-funded bioinformatics research.
• India: Expected to hit USD 1,500 million by 2034, with a CAGR of 14.3%, contributing 13.4% due to expanding pharmaceutical R&D outsourcing.
• South Korea: Projected at USD 900 million by 2034, growing at a CAGR of 13.1%, comprising 8% share through bioinformatics infrastructure development.
• Singapore: Anticipated to reach USD 600 million by 2034, with a CAGR of 12.9%, contributing 5.3% due to smart health initiatives and research grants.

MIDDLE EAST & AFRICA

The bioinformatics market in the Middle East & Africa is gradually expanding, with growing awareness of genomics and personalized medicine. Investment in healthcare infrastructure and collaborations with international research institutions are enhancing the region's bioinformatics capabilities. However, challenges such as limited funding and skilled personnel availability may impact the pace of growth.

The Middle East and Africa bioinformatics market is projected to grow to USD 5,280 million by 2034, with a CAGR of 12.0%, holding approximately 11.1% of the global market, driven by disease-specific research and tech investments.

Middle East and Africa - Major Dominant Countries in the “Bioinformatics Market”

• Israel: Estimated at USD 1,500 million by 2034, growing at a CAGR of 12.8%, representing 28.4% share due to AI-driven genomic platforms.
• United Arab Emirates: Expected to hit USD 1,100 million by 2034, with a CAGR of 11.9%, contributing 20.8% via digital transformation in healthcare.
• Saudi Arabia: Projected at USD 1,000 million by 2034, expanding at a CAGR of 11.7%, holding 18.9% market share through national biotechnology initiatives.
• South Africa: Forecasted at USD 900 million by 2034, with a CAGR of 11.5%, comprising 17.0% of the regional share through clinical research growth.
• Nigeria: Anticipated to reach USD 780 million by 2034, with a CAGR of 11.0%, making up 14.8% of the market supported by medical research collaborations.

List of Top Bioinformatics Companies

• Genoox
• Seven Bridges Genomics
• BGI
• Genedata
• Interpace Diagnostics
• QIAGEN
• Thermo Fisher Scientific
• Fabric Genomics
• Genomatrix (Intrexon)
• Agilent Technologies
• Codexis
• Biomax Informatics AG
• Tempus
• Eurofins Scientific
• Illumina
• DNAnexus
• Wuxi NextCODE
• Oxford Gene Technology

Top Two Companies with Highest Market Share

• Thermo Fisher Scientific: Thermo Fisher Scientific holds the largest share of the global bioinformatics market, accounting for approximately 14.6% in 2025. The company’s bioinformatics division offers integrated sequencing platforms, AI-enhanced data analytics, and cloud-based genomic services. In 2025, Thermo Fisher processed over 2.1 million whole-genome sequences globally, with over 72% of its bioinformatics customers coming from the pharmaceutical and clinical diagnostics sectors. Its strong M&A strategy and investment in AI-driven bioinformatics pipelines have strengthened its dominance in North America and Europe.
• Illumina: Illumina ranks second with an estimated 12.9% share of the bioinformatics market in 2025. The company is renowned for its sequencing hardware, software, and bioinformatics solutions used in clinical genomics, agriculture, and academic research. In 2025, Illumina’s cloud-based sequencing suite processed over 1.8 billion reads per day across 40+ countries. Its collaborations with national genome projects in the USA, UK, and China have expanded its market reach, and 65% of its bioinformatics revenue now comes from integrated sequencing and analysis platforms.

Investment Analysis and Opportunities

The bioinformatics market presents lucrative investment opportunities, driven by technological advancements and the increasing integration of bioinformatics in healthcare and agriculture. Investors are focusing on companies that offer innovative solutions in data analysis, cloud computing, and AI integration. The growing demand for personalized medicine and the expansion of genomics research are attracting significant funding from both public and private sectors. Additionally, emerging markets in the Asia-Pacific region offer potential for investment, given their expanding research infrastructure and supportive government policies.

New Product Development

The bioinformatics market is undergoing rapid transformation, driven by an intense focus on product innovation and enhanced data analysis capabilities. Companies across the globe are allocating substantial R&D budgets to introduce cutting-edge bioinformatics tools that cater to growing demands from healthcare, pharmaceutical, agriculture, and life science sectors. In 2025, over 52% of global bioinformatics providers reported launching at least one new product, reflecting a strong innovation pipeline. One of the most notable innovations is the development of AI-powered genomic data processing platforms. Thermo Fisher Scientific released a comprehensive AI-enhanced suite in early 2025 capable of analyzing up to 1.2 million sequencing reads per hour, reducing research turnaround time by nearly 58%. Illumina unveiled a real-time sequencing software platform with integrated predictive modeling, enhancing diagnostic yield in oncology by 44%. In addition, Genedata and QIAGEN launched modular platforms allowing researchers to customize analysis workflows based on project requirements. These tools also offer multi-omics integration capabilities, enabling users to simultaneously analyze genomic, transcriptomic, and proteomic datasets. Cloud-native bioinformatics solutions have also gained traction. Over 68% of new software products introduced in 2025 offer full cloud compatibility, ensuring better scalability, cross-border collaboration, and secure data management. The continued emergence of intuitive, user-friendly interfaces has enabled non-bioinformatics professionals to adopt these technologies, expanding the overall market penetration.

Five Recent Developments

• Thermo Fisher Scientific (2024): Launched a transcriptomics software suite with AI integration, reducing large-scale gene expression analysis time by 60%. Over 1,000 research centers adopted the software by Q2 2025.
• Illumina (2023): Introduced a real-time cloud-sequencing platform supporting 70% faster data processing and deployed across 35 countries within 12 months of release.
• QIAGEN (2025): Released an open API bioinformatics toolkit compatible with 95% of public databases, enhancing data flexibility and third-party platform integration.
• DNAnexus (2024): Enabled petabyte-scale genomic data handling through a new cloud-based infrastructure, supporting over 20 petabytes of data across 12 major biopharma partnerships by early 2025.
• Genedata (2025): Delivered a machine learning-driven proteomics module that improved protein identification accuracy by 38%, supporting faster biomarker validation in clinical trials.

Report Coverage of Bioinformatics Market

The Bioinformatics Market Report provides a detailed and structured assessment of the global market landscape, enabling stakeholders to make informed strategic decisions. Covering the entire value chain, the report offers in-depth Bioinformatics Market Analysis, profiling critical segments, leading players, and major technological developments from 2023 to 2025. The scope of the report includes the breakdown of the market by type, such as genomics, transcriptomics, metabolomics, proteomics, chemoinformatics, and molecular phylogenetics, and by application, including knowledge management tools, bioinformatics platforms, and bioinformatics services. Each segment includes real-time data points and measurable performance indicators. This Bioinformatics Industry Report also highlights strategic developments such as mergers, acquisitions, product launches, research collaborations, and funding inflows, with over 84 notable activities tracked between 2023 and 2025. The report covers performance across North America, Europe, Asia-Pacific, and Middle East & Africa, offering region-specific Bioinformatics Market Insights an

Bioinformatics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 12922 Million in 2026
Market Size Value By	USD 39661.02 Million by 2035
Growth Rate	CAGR of 13.27% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Knowledge Management Tools Bioinformatics Platform Bioinformatics Services By Application : Metabolomics Molecular Phylogenetics Transcriptomics Proteomics Chemoinformatics Genomics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample